Vaishali Pharma Limited (NSEI: VAISHALI)
Health Care · Pharmaceuticals · IN
Rs7.99
-6.11% today · -33.9% 1Y
Vaishali Pharma Limited (NSEI: VAISHALI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $10.89M and employs 27 people.
Over the last twelve months the share price has lost 33.9%, trading between 4.75 and 12.75.
Tweenvest scores Vaishali Pharma Limited across four factors: quality 57/100, value 37/100, growth 76/100. Its strongest factor is growth.
VAISHALI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.89M
- Revenue (TTM)
- $11.41M
- P/E
- 23.58
- EPS
- 0.34
- Dividend yield
- —
- Beta (5Y)
- 0.36
- 52-week high
- Rs12.75
- 52-week low
- Rs4.75
- Avg volume (3M)
- —
- Shares outstanding
- 130.46M
- Employees
- 27
- Next earnings
- —
About Vaishali Pharma Limited
Vaishali Pharma Limited functions as a pharmaceutical enterprise, conducting its business both within India and across global markets. The company's extensive product portfolio encompasses Active Pharmaceutical Ingredients (APIs), covering a broad spectrum of therapeutic areas. These include substances used in the treatment of bacterial infections (antibiotics), digestive issues (anti-ulcer), pain and inflammation (anti-inflammatory, analgesic, antipyretic), malaria, cardiovascular conditions, diabetes, common cold and allergies, diarrheal and parasitic diseases, viral infections, epilepsy, asthma, fungal infections, blood clot prevention (anti-platelet agents), muscle relaxation, and parasitic worm infections (anti-helmintics). Beyond these, Vaishali Pharma also supplies excipients, topical steroids, corticosteroids, and various enzymes. In addition to APIs, the company manufactures and distributes a diverse range of finished pharmaceutical formulations. These include prepared medications for bacterial infections, anti-platelet actions, laxative effects, digestive/enzyme support, asthma, malaria, cold/allergy/viral symptoms, psychotic disorders, fungal infections, pain/inflammation, diabetes, cardiac ailments, vitamin deficiencies, and topical steroid/corticosteroid applications, among other general formulations. Furthermore, its offerings extend to specialized segments such as veterinary pharmaceuticals, nutraceuticals, oncology products, herbal remedies, and surgical supplies. Established in 1989, the company maintains its corporate headquarters in Mumbai, India.
- ISIN
- INE972X01022
- Founded
- 1989
- Listed since
- Aug 22, 2017
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,234.92 | +0.10% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.25 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.27 | -0.12% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.70 | -0.03% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.52 | -0.99% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.